Fig. 2

MRS5980 prevents cisplatin-induced sensorimotor deficits, mechanical allodynia and spontaneous pain. Mice were treated with cisplatin and MRS5980 as in Fig. 1A and sensorimotor deficits, mechanical allodynia and spontaneous pain were measured after completion of all cognitive tests. a–c Influence of MRS5980 on sensorimotor function in the beam walking test. Male and female mice were tested on three different beams of increasing difficulty. Data are expressed as the time it takes to reach the escape platform at the end of the wide flat (a), narrow flat (b), and round beam (c). Black circles: male mice, n = 7–8 and grey circles: female mice, n = 6–8 per group. d Mechanical sensitivity expressed as 50% paw withdrawal threshold was assessed using von Frey hairs. Black circles: male mice, n = 7–8 and grey circles: female mice, n = 6–8 per group. e Effect of MRS5980 on the cisplatin-induced spontaneous pain as measured in the conditional place preference test (CPP). Y-axis indicates the change in time spent in the bright (analgesic-paired chamber) between test and baseline. Black circles: male mice n = 4 and grey circles: female mice, n = 4 per group. Results are expressed as mean ± SEM; Two-way ANOVA with Tukey's post-hoc analysis ***p ≤ 0.001; ****p ≤ 0.0001. No significant sex effects were detected